Acetazolamide for Type 2 Diabetes
(DIPPER Pilot Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The study aims to determine the acute efficacy and safety of three sequential doses of acetazolamide (62.5 mg, 125 mg, 250 mg) each for 2 weeks in 20 patients with T2D receiving background SGLT2i therapy.
Who Is on the Research Team?
David Z.I Cherney, MD CM, PhD, FRCPC
Principal Investigator
University Health Network, Toronto General Hospital
Are You a Good Fit for This Trial?
This trial is for adults with type 2 diabetes who are already taking an SGLT2 inhibitor medication. Participants should be generally healthy aside from their diabetes and able to safely take the study drugs.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Acetazolamide
- Dapagliflozin
Trial Overview
Researchers are testing three different doses of acetazolamide (62.5 mg, 125 mg, and 250 mg), each taken for two weeks, in people with type 2 diabetes who are already on dapagliflozin (an SGLT2 inhibitor). The goal is to see how safe and effective these combinations are.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients will be up-titrated starting at acetazolamide 62.5 mg twice daily for 2 weeks, followed by a 2-week washout period. This sequence will be repeated with acetazolamide doses of 125 mg twice daily for 2 weeks and 250 mg twice daily for 2 weeks, with each treatment period followed by a 2-week washout period.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.